Acquiring Company
Argenx SE
Acquired Company
Forte Biosciences
AmsterdamBiotechnologyHealth CareTherapeuticsDescription
Argenx SE has successfully acquired Forte Biosciences through a cash tender offer valued at $77.00 per share, finalized on August 27, 2026. This acquisition enhances Argenx's immunology pipeline and integrates clinical-stage assets from Forte. The deal reflects Argenx's commitment to expanding its investment in biotechnology and pharmaceuticals, further solidifying its market position.
Don't miss Argenx SE's next move
Get an email the moment Argenx SE makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Forte Biosciences?
Forte Biosciences was acquired by Argenx SE, based in Amsterdam. The deal was reported on September 13, 2026. Argenx SE is a biotechnology company focused on creating novel therapies for patients with autoimmune diseases. Their innovative approach centers around the development of human antibody-based treatments. Argenx SE is publicly traded (ARGX) and operates in Biotechnology.
When did Argenx SE acquire Forte Biosciences?
Argenx SE's acquisition of Forte Biosciences was reported on September 13, 2026. Argenx SE has successfully acquired Forte Biosciences through a cash tender offer valued at $77.00 per share, finalized on August 27, 2026. This acquisition enhances Argenx's immunology pipeline and integrates clinical-stage assets from Forte. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Forte Biosciences do?
Forte Biosciences is the company acquired in this transaction. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.